Hantavirus Translational Modelling Capability

AI SummaryClose X

Physiomics plc has demonstrated its hantavirus translational modelling capability, developing a framework that integrates in vitro antiviral screening, concentration-response potency modelling, pharmacokinetic exposure translation, mechanistic PK/PD viral dynamics, and virtual population simulations to assess the potential for viral suppression in humans. This initiative highlights the company's quantitative pharmacology and mechanistic modelling expertise within infectious disease applications, with potential broader applicability to other viral threats like Ebola. While this framework is for scientific and illustrative purposes and has no commercial application yet, it showcases Physiomics' ability to support infectious disease therapeutic development by linking preclinical data with human exposure and dosing feasibility.

Disclaimer*

Companies

Physiomics (PYC)
UK 100

Latest directors dealings